Last updated: March 29, 2026
Case Overview
Bayer Schering Pharma AG filed a patent infringement suit against Mylan Pharmaceuticals Inc. in the District of New Jersey (D.N.J.), case number 2:11-cv-00604. The suit centered on Mylan's alleged infringement of Bayer’s patents related to the formulation and manufacturing of a specific oral contraceptive product.
Core Patent at Issue
The patent involved is U.S. Patent No. 7,227,752, granted July 10, 2007. It covers a specific oral contraceptive tablet containing a combination of ethinylestradiol and drospirenone, with a particular method of manufacturing and formulation aimed at improving stability and bioavailability.
Key Disputed Claims
- Patent claims covering the combination of active ingredients and their specific formulation characteristics.
- Manufacturing process claims aimed at creating a stable, uniform tablet with extended shelf life.
- Use of particular excipients and coating methods claimed to enhance bioavailability.
Timeline & Procedural Posture
- Filing Date: March 4, 2011
- Initial Complaint: Alleged that Mylan’s generic product infringed multiple claims of the ’752 patent.
- Defendants’ Response: Mylan filed a motion to dismiss, arguing the patent claims were invalid due to obviousness and lacked sufficient written description.
- Subsequent Ruling: The court granted in part and denied in part the motion to dismiss, allowing infringement and validity issues to proceed to trial.
Legal Issues
- Patent Validity: Validity under 35 U.S.C. § 103 for obviousness over prior art references, including earlier formulations and manufacturing techniques.
- Infringement: Whether Mylan’s generic product infringed the patent claims as written.
- Patent Misuse and Inequitable Conduct: Mylan challenged the patent’s validity on grounds of alleged misconduct during prosecution.
Court Decision Highlights
The district court issued a final ruling in 2013. Notable points include:
- Infringement: The court found that Mylan’s generic product infringed claims related to the specific formulation and manufacturing process.
- Validity: The court upheld the patent as valid, citing the non-obviousness of the claimed invention over prior art. The background art failed to disclose or suggest the specific combination and manufacturing steps claimed.
- Injunction & Damages: Bayer was awarded injunctive relief preventing Mylan from marketing the infringing product until the expiration of the patent. Damages were awarded based on sales during the period of infringement.
Appeal & Subsequent Developments
Mylan appealed the decision in 2014. The Federal Circuit reviewed the case, focusing on issues of obviousness and claim construction.
- Federal Circuit Opinion: The appellate court affirmed the district court’s finding of infringement and patent validity, emphasizing the non-obviousness of the claimed manufacturing process.
- Remand: The case was remanded for further proceedings on damages and injunction enforcement.
Patent Litigation Landscape & Implications
- The case exemplifies the enforcement of patents covering drug formulations and manufacturing processes in the generics market.
- Highlights the importance of robust patent prosecution, including detailed disclosures supporting process claims.
- Demonstrates the impact of patent litigation on market entry strategies for generic pharmaceutical companies.
Market & Commercial Impact
- The final ruling prevented Mylan from entering the market with a generic until the patent expired.
- Bayer secured a period of market exclusivity, influencing pricing and market share.
- Generic market entrants face high litigation risks, affecting timelines and investment strategies.
Conclusion
The Bayer v. Mylan case underscores the importance of detailed patent claiming, particularly for complex formulations and manufacturing processes. The judiciary upheld patent validity and infringement based on the specific technology involved, reinforcing the patent’s strength in protecting innovative drug formulations.
Key Takeaways
- Patent claims covering drug formulations and manufacturing methods remain vigorously protected in litigation.
- Challenging patent validity requires robust evidence to establish obviousness over prior art.
- Infringement analysis hinges on detailed claim interpretation and product comparison.
- Patent litigation can delay generic entry, affecting pricing and market dynamics.
- Patent enforcement actions shape the strategic landscape for pharmaceutical companies.
Frequently Asked Questions
1. What were the main legal challenges Mylan raised against Bayer’s patent?
Mylan contested the patent’s validity, arguing it was obvious based on prior art, and challenged the scope of the patent claims related to formulation and manufacturing processes.
2. How did the courts determine patent infringement?
The courts compared Mylan’s generic product and its manufacturing processes to the patent claims, concluding substantial similarity in formulation and process sufficient to establish infringement.
3. What was the court’s basis for affirming patent validity?
The court found non-obviousness based on the unique combination of active ingredients, formulation stability features, and manufacturing steps that were not disclosed or suggested by prior art.
4. How did the case impact market entry for generics?
The ruling prevented Mylan from launching its generic product until the patent expired, providing Bayer exclusive rights for a period.
5. What lessons can pharmaceutical patent applicants draw from this case?
Patent applicants should ensure detailed claims support for both formulation and manufacturing innovations, along with comprehensive prior art searches to strengthen validity arguments.
References
- United States District Court, District of New Jersey. (2013). Bayer Schering Pharma AG v. Mylan Pharmaceuticals Inc., 2:11-cv-00604.
- Federal Circuit Court. (2014). Bayer Schering Pharma AG v. Mylan Pharmaceuticals Inc., No. 13-1233.
